Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 9/2009

01-09-2009

Improvement in glycemic control by gastric electrical stimulation (TANTALUSTM) in overweight subjects with type 2 diabetes

Authors: A. Bohdjalian, B. Ludvik, B. Guerci, L. Bresler, E. Renard, D. Nocca, E. Karnieli, A. Assalia, R. Prager, G. Prager

Published in: Surgical Endoscopy | Issue 9/2009

Login to get access

Abstract

Background

The TANTALUS system (MetaCure Ltd.) is a minimally invasive implantable gastric stimulation modality that does not exhibit malabsorptive or restrictive characteristics. The device applies gastric contractility modulation (GCM) signals to the stomach antrum. The signals are delivered in synchronization to the native electrical activity of the stomach during meals. Retrospective analysis of previous studies indicated that type 2 diabetes mellitus (T2DM) subjects on oral medication with hemoglobin A1c (HbA1c) between 7.5% and 9.5% are the population with most potential benefit from the treatment. The current study includes subjects enrolled prospectively within that range of HbA1c.

Aim

To prospectively investigate the potential effect of the TANTALUS system on glycemic control and weight in overweight subjects with T2DM.

Methods

In this European multicenter, open-label study, 13 T2DM obese (6 male, 7 female, BMI 37.2 ± 1.0 kg/m2, range 30.4–44.0 kg/m2) subjects treated with oral antidiabetic medications but with poor glycemic control (HbA1c ≥ 7%, range 7.3–9.5%) were implanted laparoscopically with the TANTALUS system.

Results

Thirteen subjects that had completed 3 months of treatment showed a significant reduction in HbA1c from 8.0 ± 0.2% to 6.9 ± 0.1% (p < 0.05), whereas fasting blood glucose decreased from 175 ± 6 mg/dL to 127 ± 8 mg/dL (p < 0.05). The glycemic improvement was accompanied by reduction in weight from 104.4 ± 4.4 kg to 99.7 ± 4.8 kg, and in waist circumference from 122.3 ± 3.2 cm to 117.0 ± 3.0 cm.

Conclusions

Interim results with the TANTALUS system suggest that this stimulation regime can potentially improve glucose levels and induce moderate weight loss in obese T2DM subjects on oral antidiabetic therapy with poor glycemic control. Further evaluation is required to determine whether this effect is due to induced weight loss and/or due to direct signal-dependent mechanisms.
Literature
1.
Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM (2004) The evolving diabetes burden in the United States. Ann Intern Med 140:945–950PubMed
2.
Kopelman PG, Hitman GA (1998) Diabetes: exploding type II. Lancet 352(Suppl. 4):5CrossRef
3.
Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I (2005) Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care 28:1353–1357PubMedCrossRef
4.
Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117:574–584PubMedCrossRef
5.
Ferchak CV, Meneghini LF (2004) Obesity, bariatric surgery and type 2 diabetes–a systematic review. Diabetes Metab Res Rev 20:438–445PubMedCrossRef
6.
Moo TA, Rubino F (2008) Gastrointestinal surgery as treatment for type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2:153–158
7.
Peles S, Petersen J, Aviv R, Policker S, Abu-Hatoum O, Ben-Haim SA, Gutterman DD, Sengupta JN (2003) Enhancement of antral contractions and vagal afferent signaling with synchronized electrical stimulation. Am J Physiol Gastrointest Liver Physiol 285:G577–G585PubMed
8.
Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:1687–1694PubMedCrossRef
9.
Crowell MD, Decker GA, Levy R, Jeffrey R, Talley NJ (2006) Gut–brain neuropeptides in the regulation of ingestive behaviors and obesity. Am J Gastroenterol 101:2848–2856PubMedCrossRef
10.
Druce M, Bloom SR (2003) Central regulators of food intake. Curr Opin Clin Nutr Metab Care 6:361–367PubMedCrossRef
11.
Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, Riener R, Zacherl J, Ludvik B (2006) One-year experience with Tantalus: a new surgical approach to treat morbid obesity. Obes Surg 5:627–634CrossRef
12.
Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L, Rossetti L (2005) Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434:1026–1031PubMedCrossRef
13.
Neeley WE (1972) Simply automated determination of serum or plasma glucose by a hexokinase/glucose-6-phosphate dehydrogenase method. Clin Chem 18:509–515PubMed
14.
Dunn PJ, Cole RA, Soeldner JS (1979) Further development and automation of a high pressure liquid chromatography method for the determination of glycosylated hemoglobins. Metabolism 28:777–779PubMedCrossRef
15.
Yin J, Chen JD (2008) Implantable gastric electrical stimulation: ready for prime time? Gastroenterology 134:665–667PubMedCrossRef
16.
De Vries J, De Jongste MJ, Spincemaille G, Staal MJ (2007) Spinal cord stimulation for ischemic heart disease and peripheral vascular disease. Adv Tech Stand Neurosurg 32:63–89PubMedCrossRef
17.
Green AL, Wang S, Bittar RG, Owen SL, Paterson DJ, Stein JF, Bain PG, Shlugman D, Aziz TZ (2007) Deep brain stimulation: a new treatment for hypertension? J Clin Neurosci 14:592–595PubMedCrossRef
18.
North RB, Roark GL (1995) Spinal cord stimulation for chronic pain. Neurosurg Clin N Am 6:145–155
19.
Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, Mika Y, Rousso B, Burkhoff D, Ben-Haim S, Sabbah HN (2007) Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 21:2120–2128CrossRef
20.
Dockray GJ (2003) The Brain–Gut Axis. In: Yamada T (ed) Basic Mechanisms of Normal and Abnormal Gastrointestinal Function, 4th edn. Lippincott Williams & Wilkins, PA, pp 77–91
21.
Cigaina V, Hirschberg AL (2003) Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin. Obes Res 11:1456–1462PubMedCrossRef
22.
Sobocki J, Thor PJ, Uson J, Diaz-Guemes I, Lipinski M, Calles C, Pascual S (2001) Microchip vagal pacing reduces food intake and body mass. Hepatogastroenterology 48:1783–1787PubMed
23.
Shikora SA (2004) “What are the Yanks doing?” The U.S. experience with implantable gastric stimulation (IGS) for the treatment of obesity—update on the ongoing clinical trials. Obes Surg Suppl 1:S40–S48CrossRef
24.
Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:1687–1694PubMedCrossRef
25.
Andrews PL, Sanger GJ (2002) Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 6:650–656CrossRef
26.
Strader AD, Woods SC (2005) Gastrointestinal hormones and food intake. Gastroenterology 128:175–191PubMedCrossRef
27.
Liu S, Lei Y, Chen JD (2006) Inhibitory effects and mechanisms of colonic electric stimulation on gastric and rectal tone in conscious dogs. Dis Colon Rectum 49:1749–1754PubMedCrossRef
28.
Sanmiguel CP, Haddad W, Aviv R, Cunneen SA, Phillips EH, Kapella W, Soffer EE (2007) The TANTALUS trade mark system for obesity: effect on gastric emptying of solids and ghrelin plasma levels. Obes Surg 17:1503–1509PubMedCrossRef
Metadata
Title
Improvement in glycemic control by gastric electrical stimulation (TANTALUSTM) in overweight subjects with type 2 diabetes
Authors
A. Bohdjalian
B. Ludvik
B. Guerci
L. Bresler
E. Renard
D. Nocca
E. Karnieli
A. Assalia
R. Prager
G. Prager
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 9/2009
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-008-0222-4

Other articles of this Issue 9/2009

Surgical Endoscopy 9/2009 Go to the issue

OriginalPaper

Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions

OriginalPaper

Predictors of immediate bleeding during endoscopic submucosal dissection in gastric lesions

OriginalPaper

Development of an articulating ultrasonically activated device for laparoscopic surgery

Technique

Intracorporeal esophagojejunal anastomosis after laparoscopic total gastrectomy for patients with gastric cancer

OriginalPaper

For patients with predicted low risk for choledocholithiasis undergoing laparoscopic cholecystectomy, selective intraoperative cholangiography and postoperative endoscopic retrograde cholangiopancreatography is an effective strategy to limit unnecessary procedures

OriginalPaper

Measurement of gastric pH in ambulatory esophageal pH monitoring